|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Giovanni Caforio M.D.||Chairman & CEO||5,82M||N/D||1965|
|Mr. David V. Elkins||Exec. VP & CFO||3,18M||1,3M||1968|
|Ms. Sandra Leung Esq.||Exec. VP & Gen. Counsel||2,73M||N/D||1961|
|Dr. Christopher S. Boerner||Exec. VP & Chief Commercialization Officer||2,61M||N/D||1971|
|Mr. Rupert Vessey BCH, BM, DPHIL, M.A.||Exec. VP and Pres of Research & Early Devel.||3,21M||1,45M||1965|
|Mr. Greg Meyers||Exec. VP and Chief Digital & Technology Officer||N/D||N/D||1973|
|Mr. Paul von Autenried||Exec. VP & Chief Information Officer||N/D||N/D||1962|
|Mr. Timothy Power||VP & Head of Investor Relations||N/D||N/D||N/D|
|Ms. Cari Gallman||Chief Compliance & Ethics Officer||N/D||N/D||N/D|
|Ms. Ann M. Powell Judge||Exec. VP & Chief HR Officer||N/D||N/D||1966|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
L'ISS Governance QualityScore di Bristol-Myers Squibb Company al 1 ottobre 2022 è 2. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 3; retribuzione: 1.